Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.45 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | Q9HBH1 | 1/20 | 0.36 | |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005311 | 0.89 | CA1 (0.41) | CA1CA2TAS1R3TAS1R1ZDHHC7 | |
| SCHEMBL6006458 | 0.87 | CA1 (0.42) | CA1CA2TAS1R3TAS1R1ZDHHC7 | |
| SCHEMBL6006517 | 0.81 | ALDH1A1 (0.41) | CA1CA2ZDHHC7TSHRATM | |
| SCHEMBL6008014 | 0.80 | CA1 (0.39) | CA1CA2TAS1R3TAS1R1ZDHHC7 | |
| SCHEMBL7764581 | 0.79 | CA2 (0.57) | CA1CA2TAS1R3TAS1R1ZDHHC7 | |
| SCHEMBL7764588 | 0.79 | CA2 (0.57) | CA1CA2TAS1R3TAS1R1ZDHHC7 | |
| SCHEMBL21243821 | 0.78 | TSHR (0.43) | CA1CA2TSHRLMNA | |
| SCHEMBL8506262 | 0.77 | CA1 (0.55) | CA1CA2TAS1R3TAS1R1ZDHHC7 | |
| SCHEMBL17986775 | 0.77 | CA1 (0.55) | CA1CA2TAS1R3TAS1R1ZDHHC7 | |
| SCHEMBL7400219 | 0.76 | PDF (0.39) | CA1CA2HDAC2CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200129458-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3438091-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-20190022039-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2019-01-24 | — | — | US | disclosed |
| US-9045423-B2 | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient | KOWA COMPANY, LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20140249144-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | KOWA COMPANY, LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-8791090-B2 | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient | KOWA COMPANY, LTD. (JP) | 2014-07-29 | — | — | US | disclosed |
| EP-2415764-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | Kowa Company, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | KOWA COMPANY, LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129458-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | GLP1R, GPR119, GIPR | CA1 3303/4885CA2 2248/4885TAS1R3 619/4885 |
| US-20140249144-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | EPOR, HBG1, HBG2 | CA1 2873/4885CA2 2799/4885TAS1R3 2753/4885 |
| US-20190022039-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | GLP1R, GPR119, GIPR | CA1 3303/4885CA2 2248/4885TAS1R3 619/4885 |
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | EPOR, HBG1, HBG2 | CA1 2873/4885CA2 2799/4885TAS1R3 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.